Skip to main content
Equibles
PSNL logo

PSNL · Personalis, Inc. · Earnings Call Transcripts & Audio

Track PSNL — free

Use PSNL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PSNL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$16.21 -0.12 (-0.73%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$1.73B
Shares
106.80M

Personalis, Inc. Earnings Call Transcripts

Quarterly earnings calls for Personalis, Inc. (PSNL), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼15.8% $18.24M −$27.55M '22 Q2 22-08-03 ▼33.3% $14.86M −$26.49M '22 Q3 22-11-02 ▼19.1% $16.72M −$31.07M '22 Q4 23-02-23 ▲23.9% $18.86M −$28.66M '23 Q1 23-05-03 ▼8.4% $16.70M −$23.95M '23 Q2 23-08-08 ▲22.8% $18.25M −$29.10M '23 Q3 23-11-07 ▲17.7% $19.68M −$26.58M '23 Q4 24-02-28 ▲3.5% $19.52M −$12.97M '24 Q1 24-05-08 ▲35.2% $22.58M −$12.80M '24 Q2 24-08-07 ▲40.9% $25.71M −$39.09M '24 Q3 24-11-06 ▲5.5% $20.61M −$15.75M '25 Q1 25-05-06 ▼23.8% $17.20M −$20.06M '25 Q2 25-08-05 ▼43.6% $14.49M −$21.65M '25 Q3 25-11-04 ▲3.2% $17.34M −$23.81M '25 Q4 26-02-26 ▼24.9% $15.47M −$30.03M '26 Q1 26-05-07 LATEST ▲30% $22.36M −$31.68M '26 Q2 26-07-20
Earnings call
FY26 · Q2
2026-07-20
Personalis, Inc. (PSNL) Q2 2026 Earnings Call
Revenue
$22.36M
▲ 30% YoY
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript
Confident tone Clinical test volume growth and ordering physicians Reimbursement and Medicare submissions Biopharma MRD business and backlog
Revenue
$15.47M
▼ 24.9% YoY
Diluted EPS
$-0.29
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Confident tone Medicare reimbursement coverage MRD strategy and market opportunity Clinical test volume growth
Revenue
$17.34M*
▲ 3.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript
Positive tone Medicare reimbursement and MolDX dossiers Clinical volume growth and physician adoption Clinical evidence and Phase III trial data
Revenue
$14.49M
▼ 43.6% YoY
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript
Positive tone Reimbursement / Medicare Coverage Tempus Commercial Partnership MRD Clinical Adoption (NeXT Personal)
Revenue
$17.20M
▼ 23.8% YoY
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript
Confident tone MRD strategy and NeXT Personal adoption Quarterly financial results and cash position Reimbursement and Medicare submissions
Revenue
$20.61M
▲ 5.5% YoY
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-11-06
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript
Confident tone NeXT Personal MRD product and clinical impact Reimbursement pursuit Tempus commercial partnership
Revenue
$25.71M
▲ 40.9% YoY
Diluted EPS
$-0.64
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript
Confident tone MRD / NeXT Personal Test Win-in-MRD Strategy and Pillars Biopharma Growth
Revenue
$22.58M
▲ 35.2% YoY
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript
Confident tone MRD strategy and NeXT Personal launch NeXT Dx / Tempus relationship Natera collaboration
Revenue
$19.52M
▲ 3.5% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
Confident tone Biopharma and enterprise partnerships Win-in-MRD strategy and NeXT Personal Clinical evidence and reimbursement
Revenue
$19.68M*
▲ 17.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript
Revenue
$18.25M
▲ 22.8% YoY
Diluted EPS
$-0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Personalis, Inc. (PSNL) Q2 2023 Earnings Call Transcript
Revenue
$16.70M
▼ 8.4% YoY
Diluted EPS
$-0.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Personalis, Inc. (PSNL) Q1 2023 Earnings Call Transcript
Revenue
$18.86M
▲ 23.9% YoY
Diluted EPS
$-0.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Personalis, Inc. (PSNL) Q4 2022 Earnings Call Transcript
Revenue
$16.72M*
▼ 19.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Personalis, Inc. (PSNL) Q3 2022 Earnings Call Transcript
Revenue
$14.86M
▼ 33.3% YoY
Diluted EPS
$-0.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Personalis, Inc. (PSNL) Q2 2022 Earnings Call Transcript
Revenue
$18.24M
▼ 15.8% YoY
Diluted EPS
$-0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Personalis, Inc. (PSNL) Q1 2022 Earnings Call Transcript
Revenue
$15.23M
▼ 27.1% YoY
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Personalis, Inc. (PSNL) Q4 2021 Earnings Call Transcript
Revenue
$20.68M*
▲ 2.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Personalis, Inc. (PSNL) Q3 2021 Earnings Call Transcript
Revenue
$22.26M
▲ 12.3% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Personalis, Inc. (PSNL) Q2 2021 Earnings Call Transcript
Revenue
$21.67M
▲ 11.2% YoY
Diluted EPS
$-0.34
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Personalis, Inc. (PSNL) Q1 2021 Earnings Call Transcript
Revenue
$20.88M
▲ 9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Personalis, Inc. (PSNL) Q4 2020 Earnings Call Transcript
Revenue
$20.18M*
▲ 11.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Personalis, Inc. (PSNL) Q3 2020 Earnings Call Transcript
Revenue
$19.82M
▲ 15.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Personalis, Inc. (PSNL) Q2 2020 Earnings Call Transcript
Revenue
$19.50M
▲ 23.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Personalis, Inc. (PSNL) Q1 2020 Earnings Call Transcript
Revenue
$19.16M
▲ 36.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-25
Personalis, Inc. (PSNL) Q4 2019 Earnings Call
Revenue
$18.15M
▲ 38% YoY
Gross margin
36.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–26 of 26 earnings calls
Key facts CIK 1527753 CUSIP 71535D106 13F (30d) 83 filings 83 filers Visit website Investor relations